Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients

MeSH terms

• Adult
• Aged
• Aged, 80 and over
• Antibodies, Monoclonal, Humanized / adverse effects*
• Antibodies, Monoclonal, Humanized / therapeutic use
• Antineoplastic Agents, Immunological / adverse effects*
• Antineoplastic Agents, Immunological / therapeutic use
• Drug Eruptions / etiology*
• Female
• Humans
• Male
• Melanoma / drug therapy*
• Melanoma / mortality
• Middle Aged
• Nivolumab / adverse effects*
• Nivolumab / therapeutic use
• Programmed Cell Death 1 Receptor / antagonists & inhibitors*
• Retrospective Studies
• Skin Neoplasms / drug therapy*
• Skin Neoplasms / mortality
• Survival Rate
• Vitiligo / chemically induced*